Antibodies: what makes us stronger

References

• Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30:429–57. doi:10.1146/annurev-immunol-020711-075032.
   PubMed Web of Science ®Google Scholar
• Carter MJ, Mitchell RM, Meyer Sauteur PM, Kelly DF, Truck J. The antibody-secreting cell response to infection: kinetics and clinical applications. Front Immunol. 2017;8:630. doi:10.3389/fimmu.2017.00630.
   PubMed Web of Science ®Google Scholar
• Crowe JE Jr. Principles of broad and potent antiviral human antibodies: insights for vaccine design. Cell Host Microbe. 2017;22:193–206. doi:10.1016/j.chom.2017.07.013.
   PubMed Web of Science ®Google Scholar
• Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22:396–414. doi:10.1128/CMR.00001-09.
   PubMed Web of Science ®Google Scholar
• Brehm TT, Van Der Meirschen M, Hennigs A, Roedl K, Jarczak D, Wichmann D, Frings D, Nierhaus A, Oqueka T, Fiedler W, et al. Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. Sci Rep. 2021;11:5803. doi:10.1038/s41598-021-85081-0.
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng X, Chen J. Clinical progression and outcomes of 260 patients with severe COVID-19: an observational study. Sci Rep. 2021;11:3166. doi:10.1038/s41598-021-82943-5.
   PubMed Web of Science ®Google Scholar
• Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, Salanti G, Low N. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020;17:e1003346. doi:10.1371/journal.pmed.1003346.
   PubMed Web of Science ®Google Scholar
• Amanat F, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, Pillet S, Grattard F, Gonzalo S, Verhoeven P, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26:1033–36. doi:10.1038/s41591-020-0913-5.
   PubMed Web of Science ®Google Scholar
• Mor M, Werbner M, Alter J, Safra M, Chomsky E, Lee JC, Hada-Neeman S, Polonsky K, Nowell CJ, Clark AE, et al. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. PLoS Pathog. 2021;17:e1009165. doi:10.1371/journal.ppat.1009165.
   PubMed Web of Science ®Google Scholar
• Hansen CB, Jarlhelt I, Pérez-Alós L, Hummelshøj Landsy L, Loftager M, Rosbjerg A, Helgstrand C, Bjelke JR, Egebjerg T, Jardine JG, et al. SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals. J Immunol. 2021;206:109–17. doi:10.4049/jimmunol.2000898.
   PubMed Web of Science ®Google Scholar
• Marklund E, Leach S, Axelsson H, Nyström K, Norder H, Bemark M, Angeletti D, Lundgren A, Nilsson S, Andersson L-M, et al. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLoS One. 2020;15:e0241104. doi:10.1371/journal.pone.0241104.
   PubMed Web of Science ®Google Scholar
• Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan A, Finkin S, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–42. doi:10.1038/s41586-020-2456-9.
   PubMed Web of Science ®Google Scholar
• Huo J, Le Bas A, Ruza RR, Duyvesteyn HM, Mikolajek H, Malinauskas T, Tan TK, Rijal P, Dumoux M, Ward PN, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020. doi:10.1038/s41594-020-0469-6.
   Web of Science ®Google Scholar
• Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, et al. A new glycan-dependent CD4-binding site neutralizing antibody exerts pressure on HIV-1 in vivo. PLoS Pathog. 2015;11:e1005238. doi:10.1371/journal.ppat.1005238.
   PubMed Web of Science ®Google Scholar
• Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496:469–76. doi:10.1038/nature12053.
   PubMed Web of Science ®Google Scholar
• Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams M-R, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012;18:1688–92. doi:10.1038/nm.2985.
   PubMed Web of Science ®Google Scholar
• Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PNP, Spencer DIR, Seaman MS, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A. 2012;109:E3268–3277. doi:10.1073/pnas.1217207109.
   PubMed Web of Science ®Google Scholar
• Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TYK, Pietzsch J, Fenyo D, Abadir A, Velinzon K, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333:1633–37. doi:10.1126/science.1207227.
   PubMed Web of Science ®Google Scholar
• Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, Finzi A, Do Kwon Y, Scheid JF, Shi W, Xu L, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329:811–17. doi:10.1126/science.1192819.
   PubMed Web of Science ®Google Scholar
• Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, Brumme ZL, Brumme CJ, Baker B, et al. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol. 2009;83:2743–55. doi:10.1128/JVI.02265-08.
   PubMed Web of Science ®Google Scholar
• Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, et al. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci Transl Med. 2017;9:eaal2144. doi:10.1126/scitranslmed.aal2144.
   PubMed Web of Science ®Google Scholar
• Li H, Javid B. Antibodies and tuberculosis: finally coming of age? Nat Rev Immunol. 2018;18:591–96. doi:10.1038/s41577-018-0028-0.
   PubMed Web of Science ®Google Scholar
• Casadevall A. Antibodies to Mycobacterium tuberculosis. N Engl J Med. 2017;376:283–85. doi:10.1056/NEJMcibr1613268.
   PubMed Web of Science ®Google Scholar
• Li H, Wang -X-X, Wang B, Fu L, Liu G, Lu Y, Cao M, Huang H, Javid B. Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2017;114:5023–28. doi:10.1073/pnas.1611776114.
   PubMed Web of Science ®Google Scholar
• Correia-Neves M, Sundling C, Cooper A, Kallenius G. Lipoarabinomannan in active and passive protection against tuberculosis. Front Immunol. 2019;10:1968. doi:10.3389/fimmu.2019.01968.
   PubMed Web of Science ®Google Scholar
• Watson A, Li H, Ma B, Weiss R, Bendayan D, Abramovitz L, Ben-Shalom N, Mor M, Pinko E, Oz MB, et al. Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis. Nat Commun. 2021;12:602. doi:10.1038/s41467-021-20930-0.
   PubMed Web of Science ®Google Scholar
• Dugan HL, Guthmiller JJ, Arevalo P, Huang M, Chen Y-Q, Neu KE, Henry C, Zheng N-Y, Lan LYL, Tepora ME, et al. Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Sci Transl Med. 2020;12:eabd3601. doi:10.1126/scitranslmed.abd3601.
   PubMed Web of Science ®Google Scholar
• Wang Z, Schmidt F, Weistblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–22. doi:10.1038/s41586-021-03324-6.
   PubMed Web of Science ®Google Scholar
• Pattyn J, Van Keer S, Tjalma W, Matheeussen V, Van Damme P, Vorsters A. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus Res. 2019;8:100185. doi:10.1016/j.pvr.2019.100185.
   PubMed Web of Science ®Google Scholar